Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 28Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 14Neoplasms 8Colonic Neoplasms 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Lung Neoplasms 6Rectal Neoplasms 5Mouth Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Squamous Cell 4Carcinoma 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Skin Squamous Cell Carcinoma × Cetuximab × 30 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡